Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605863 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide for Bladder Cancer Chemoprevention
A Phase 2 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02605863: Clinical Trial Phase 2 study, sponsored by University of Rochester.
NCT02605863 is a Phase 2 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02605863, a Phase 2 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of androgen deprivation therapy through administration of enzalutamide on preventing bladder cancer recurrences in patients with non-muscle invasive bladder cancer (NMIBC).
Primary Outcome
Bladder cystoscopy, urine cytology, and pathology report
Interventions
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-01 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
Why NCT02605863 stopped before completion
NCT02605863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Enzalutamide is the first listed.
NCT02605863 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02605863 about?
NCT02605863 is a clinical study titled "Enzalutamide for Bladder Cancer Chemoprevention". The purpose of this study is to examine the effect of androgen deprivation therapy through administration of enzalutamide on preventing bladder cancer recurrences in patients with non-muscle invasive bladder cancer (NMIBC).
What is the current status of trial NCT02605863?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-01. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02605863?
The interventions under investigation include: Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02605863?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02605863's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia